Stocks · US
TXG
XNAS
10x Genomics, Inc. Class A Common Stock
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E—
P/B15.43x
P/S20.64x
EPS$-0.58
ROE-9.10%
ROA-7.29%
Dividend yield0.00%
Debt/Equity0.00
Free cash flow$121M
Returns and 52-week range
1W-10.42%
1M+28.75%
3M+115.27%
6M+269.66%
1Y+532.63%
YTD+385.32%
52W high$102.81
52W low$11.16
From 52W high-21.54%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| BridgeBio Pharma, Inc. Common Stock | $12.9B | — | — | -10.53% |
| Baxter International Inc. | $12.5B | — | 2.02 | -5.69% |
| Icon Plc | $13.0B | 38.45 | 6.71 | -1.92% |
| 페넘브라 | $12.5B | 77.78 | 8.16 | -1.59% |
| Corcept Therapeutics Inc. | $13.2B | 242.09 | 18.69 | +7.12% |
| Halozyme Therapeutics, Inc. | $12.3B | 29.72 | 85.64 | -0.43% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.